Quick Answer
HCW Biologics Inc. reported Operating Income of -$13.16 million for fiscal year 2025.
HCW Biologics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$13.16M | +55.3% |
| 2024 | -$29.46M | -14.5% |
| 2023 | -$25.72M | -70.6% |
| 2022 | -$15.08M | -12.8% |
| 2021 | -$13.37M | -129.5% |
| 2020 | -$5.82M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.29M | +10.7% | +5.0% |
| June 30, 2025 | -$3.46M | +77.1% | -76.2% |
| March 31, 2025 | -$1.97M | +73.8% | +46.6% |
| September 30, 2024 | -$3.68M | +27.4% | +75.7% |
| June 30, 2024 | -$15.14M | -235.6% | -102.0% |
| March 31, 2024 | -$7.49M | -39.8% | -47.6% |
| September 30, 2023 | -$5.08M | -26.3% | -12.6% |
| June 30, 2023 | -$4.51M | -28.5% | +15.9% |
- HCW Biologics Inc. showed an increase of +55.3% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, HCW Biologics Inc.’s operating income has declined by 126.0% (from -$5.82 million to -$13.16 million).
- The most recent figure is from HCW Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: